NASDAQ: INZY

Inozyme Pharma Inc Stock Forecast, Predictions & Price Target

The consensus among 4 Wall Street analysts covering (NASDAQ: INZY) stock is to Strong Buy INZY stock.

Out of 4 analysts, 1 (25%) are recommending INZY as a Strong Buy, 3 (75%) are recommending INZY as a Buy, 0 (0%) are recommending INZY as a Hold, 0 (0%) are recommending INZY as a Sell, and 0 (0%) are recommending INZY as a Strong Sell.

If you're new to stock investing, here's how to buy Inozyme Pharma stock.

(NASDAQ: INZY) Inozyme Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Inozyme Pharma's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast INZY's revenue for 2026 to be $1,230,127,150, with the lowest INZY revenue forecast at $158,692,209, and the highest INZY revenue forecast at $2,301,623,863. On average, 2 Wall Street analysts forecast INZY's revenue for 2027 to be $11,941,820,366, with the lowest INZY revenue forecast at $9,870,050,029, and the highest INZY revenue forecast at $14,013,590,702.

In 2028, INZY is forecast to generate $32,945,466,213 in revenue, with the lowest revenue forecast at $32,945,466,213 and the highest revenue forecast at $32,945,466,213.

According to 4 Wall Street analysts that have issued a 1 year INZY price target, the average INZY price target is $17.00, with the highest INZY stock price forecast at $23.00 and the lowest INZY stock price forecast at $14.00.

On average, Wall Street analysts predict that Inozyme Pharma's share price could reach $17.00 by Apr 10, 2025. The average Inozyme Pharma stock price prediction forecasts a potential upside of 286.36% from the current INZY share price of $4.40.

(NASDAQ: INZY) forecast ROE is N/A, which is considered weak.